Amyotrophic Lateral Sclerosis Clinical Trial
Official title:
Investigating the Effect of Muscle Training in Patients With Amyotrophic Lateral Sclerosis and Looking Into the Mechanisms Behind Development of Muscle Atrophy
Patients with neuropathic diseases are experiencing increasing muscle weakness, loss of
muscle strength and functional abilities during their illness. In healthy people, regular
exercise is the best way to maintain or improve muscle strength, endurance and general
health status and thereby maintain functioning abilities. Previously, patients with
neuromuscular diseases were advised to avoid any kind of physical exercise. However, lately
a number of studies have evaluated the effect of training in patients with neuromuscular
diseases, and positive effects on the functional abilities have been found. Based on these
findings we want to investigate the mechanisms leading to development of muscle atrophy and
loss of functional abilities, and to explore the opportunities of reducing muscle wasting
and thereby improve the course of the disease development through strength training.
The main objective is to investigate the effects of strength training on slowing disease
progression and reduce the decline in muscle strength and function in patients with
amyotrophic lateral sclerosis (ALS). In addition, the aim is to carry out detailed studies
of biological processes in muscle tissue in order to unveil mechanisms leading to muscle
atrophy, and to examine effects of a strength training program. The goal is to be able to
incorporate strength training in the treatment program of these patients in order to
maintain muscle strength and function in the individual for as long as possible.
Minimum 10 patients with the disease are included in the study. Through a 12 week period the
patients will participate in strength training 2-3 times per week. Muscles biopsies will be
taken (i) 12 weeks before commencement of strength training program, (ii) at the beginning
of training and (iii) after 12 weeks of strength training. Patients will function as their
own controls. Blood samples will be collected simultaneously in order to follow the
development of the strength training. Furthermore, participants will be assessed through at
number of functional tests and questionnaires evaluating their strength, balance and social/
psychological status.
Subjects are recruited through their association with Odense University Hospital. In the
present study, the participants become part of a social network, while participating in
organized training sessions, and thus have a possibility to make contact with other ALS
patients in the same situation as themselves.
n/a
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04428775 -
A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease
|
Phase 2 | |
Recruiting |
NCT04998305 -
TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps
|
Phase 1/Phase 2 | |
Recruiting |
NCT05951556 -
Telehealth Implementation of Brain-Computer Interface
|
N/A | |
Terminated |
NCT04579666 -
MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
Recruiting |
NCT04082832 -
CuATSM Compared With Placebo for Treatment of ALS/MND
|
Phase 2/Phase 3 | |
Completed |
NCT01925196 -
Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
|
||
Completed |
NCT02496767 -
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
|
Phase 3 | |
Recruiting |
NCT04816227 -
Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments
|
||
Active, not recruiting |
NCT04494256 -
A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation
|
Phase 1/Phase 2 | |
Completed |
NCT03706391 -
Study of ALS Reversals 4: LifeTime Exposures
|
||
Recruiting |
NCT04882904 -
Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part.
|
N/A | |
Completed |
NCT04557410 -
Open Label Study: Treatment of ALS Fatigue With PolyMVA
|
Phase 1 | |
Active, not recruiting |
NCT04948645 -
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis
|
Phase 1 | |
Not yet recruiting |
NCT04089696 -
Validation of the "ExSpiron©" in Patients With ALS
|
N/A | |
Not yet recruiting |
NCT06450691 -
Modeling Amyotrophic Lateral Sclerosis With Fibroblasts
|
N/A | |
Not yet recruiting |
NCT04220190 -
RAPA-501 Therapy for ALS
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05860244 -
Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients
|
Phase 2 | |
Recruiting |
NCT02917681 -
Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03067857 -
Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT02874209 -
Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis
|
N/A |